Independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC).
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company's presentation on September 9, 2019 in New York City.
These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found at Genprex.com.
Genprex's Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference in New York City on September 4, 2019.
Company’s recent performance sets path for future milestones, commercialization
Genprex's newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies.
Genprex has initiated the first phase of branding its lead drug candidate and has completed the creation and submission of non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (USAN) Council.
Genprex today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC).